Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Public ClinicalTrials.gov record NCT02975206. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults And Adolescents With A History Of Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Study identification
- NCT ID
- NCT02975206
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 484 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2016 (Actual)
- Primary completion
- Jan 16, 2018 (Actual)
- Completion
- Feb 23, 2018 (Actual)
- Last update posted
- May 20, 2021
2016 – 2018
United States locations
- U.S. sites
- 52
- U.S. states
- 23
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site 332 | Anniston | Alabama | — | — |
| Study Site 363 | Birmingham | Alabama | — | — |
| Study Site 340 | Hoover | Alabama | — | — |
| Study Site 364 | Glendale | Arizona | — | — |
| Study Site 334 | Cerritos | California | — | — |
| Study Site 386 | Encinitas | California | — | — |
| Study Site 366 | Fountain Valley | California | — | — |
| Study Site 338 | Los Angeles | California | — | — |
| Study Site 383 | North Hollywood | California | — | — |
| Study Site 374 | Oceanside | California | — | — |
| Study Site 347 | San Diego | California | — | — |
| Study Site 356 | San Diego | California | — | — |
| Study Site 333 | San Francisco | California | — | — |
| Study Site 376 | Santa Monica | California | — | — |
| Study Site 358 | Denver | Colorado | — | — |
| Study Site 370 | Jacksonville | Florida | — | — |
| Study Site 331 | Miami | Florida | — | — |
| Study Site 348 | Miami | Florida | — | — |
| Study Site 378 | Miami | Florida | — | — |
| Study Site 353 | Pinellas Park | Florida | — | — |
| Study Site 368 | Tampa | Florida | — | — |
| Study Site 377 | Tampa | Florida | — | — |
| Study Site 369 | Atlanta | Georgia | — | — |
| Study Site 349 | Savannah | Georgia | — | — |
| Study Site 381 | Chicago | Illinois | — | — |
| Study Site 360 | New Albany | Indiana | — | — |
| Study Site 380 | Bardstown | Kentucky | — | — |
| Study Site 344 | Louisville | Kentucky | — | — |
| Study Site 379 | Boston | Massachusetts | — | — |
| Study Site 350 | Warren | Michigan | — | — |
| Study Site 371 | Saint Joseph | Missouri | — | — |
| Study Site 387 | Las Vegas | Nevada | — | — |
| Study Site 352 | Berlin | New Jersey | — | — |
| Study Site 375 | Forest Hills | New York | — | — |
| Study Site 373 | Rochester | New York | — | — |
| Study Site 341 | High Point | North Carolina | — | — |
| Study Site 355 | Shelby | North Carolina | — | — |
| Study Site 337 | Oklahoma City | Oklahoma | — | — |
| Study Site 345 | Johnston | Rhode Island | — | — |
| Study Site 362 | Providence | Rhode Island | — | — |
| Study Site 382 | Anderson | South Carolina | — | — |
| Study Site 343 | Spartanburg | South Carolina | — | — |
| Study Site 357 | Chattanooga | Tennessee | — | — |
| Study Site 365 | Austin | Texas | — | — |
| Study Site 335 | Houston | Texas | — | — |
| Study Site 359 | Pflugerville | Texas | — | — |
| Study Site 339 | Plano | Texas | — | — |
| Study Site 361 | San Antonio | Texas | — | — |
| Study Site 351 | Draper | Utah | — | — |
| Study Site 342 | Norfolk | Virginia | — | — |
| Study Site 336 | Richmond | Virginia | — | — |
| Study Site 367 | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02975206, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2021 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02975206 live on ClinicalTrials.gov.